Analysis
Personalised medicine: not just in our genes
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2161 (Published 03 April 2012) Cite this as: BMJ 2012;344:e2161Data supplement
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Table A: Methods of literature search
- Data Supplement - Table B: Repurposed randomised trials analysing pharmacogenetic interactions
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Table A: Methods of literature search
- Data Supplement - Table B: Repurposed randomised trials analysing pharmacogenetic interactions
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Table A: Methods of literature search
- Data Supplement - Table B: Repurposed randomised trials analysing pharmacogenetic interactions
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Table A: Methods of literature search
- Data Supplement - Table B: Repurposed randomised trials analysing pharmacogenetic interactions
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Table A: Methods of literature search
- Data Supplement - Table B: Repurposed randomised trials analysing pharmacogenetic interactions
Related articles
See more
- Cancer drugs remain FDA approved despite lack of benefit, study findsBMJ December 06, 2016, 355 i6568; DOI: https://doi.org/10.1136/bmj.i6568
- Johnson & Johnson is ordered to pay $1bn over faulty hip implantsBMJ December 06, 2016, 355 i6551; DOI: https://doi.org/10.1136/bmj.i6551
- Bill to boost medical research funding and speed drug approval passes US houseBMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498
- Trial of novel leukaemia drug is stopped for second time after two more deathsBMJ November 25, 2016, 355 i6376; DOI: https://doi.org/10.1136/bmj.i6376
- Promise of new Alzheimer’s drug is dashed after lack of evidenceBMJ November 24, 2016, 355 i6362; DOI: https://doi.org/10.1136/bmj.i6362
Cited by...
- Evaluation of person-level heterogeneity of treatment effects in published multiperson N-of-1 studies: systematic review and reanalysis
- Individualisation of drug treatments for patients with long-term conditions: a review of concepts
- Pharmacogenomic personalised medicine for antiplatelet agents is on the horizon